ASTRO has updated guidance for the use of radiation therapy and systemic therapy for patients who’ve undergone surgery for endometrial cancer. The guideline also considers the role of surgical staging and molecular profiling techniques in determining whether a patient should receive post-operative therapy.
Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.
The combination of capivasertib plus fulvestrant significantly improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive/HER2-negative advanced breast cancer, including those with AKT pathway–altered tumors.
The safety profile for the combination of tucatinib, trastuzumab, and capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic breast cancer.
Concurrent adagrasib and pembrolizumab produced preliminary activity when administered as first-line treatment in patients with non–small cell lung cancer harboring a KRAS G12C mutation, irrespective of PD-L1 status, according to data from the KRYSTAL-1 phase 1b and the KRYSTAL-7 phase 2 cohorts.
Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer.
Eribulin mesylate demonstrated a trend toward improved outcomes vs other chemotherapy options of physician’s choice in patients with HER2-low or HER2-0 metastatic breast cancer who were previously treated with at least 1 chemotherapy.
Patients with non-metastatic breast cancer undergoing treatment who added yoga to conventional exercises experienced improvements in disease-free survival, overall survival, and long-term quality of life vs those who did conventional exercises alone.
Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.
Neoadjuvant treatment with trastuzumab deruxtecan showed promising responses in patients with early-stage breast cancer.
Trastuzumab deruxtecan demonstrated a 64% reduction in the risk of disease progression or death compared with physician's choice of treatment in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who previously received ado-trastuzumab emtansine.
Oncopeptides AB announced December 7, 2022, that the FDA has asked the company to withdraw melphalan flufenamide from the US market.
Press Release
Pancreatic cancer often lurks as a silent disease. With no known symptoms, it can progress undetected and spread to other organs.
Press Release
A study published by researchers at Fox Chase Cancer Center suggests that race itself may predict disparate outcomes between patients with head and neck cancer.
The combination of vusolimogene oderparepvec and nivolumab generated promising responses in patients with cutaneous melanoma who failed previous anti–PD-1 therapy, according to initial data from the phase 2 IGNYTE trial.
The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, hormone receptor–positive breast cancer who would derive benefit from the addition of ovarian function suppression.
With patents expiring on some of the revolutionary agents in cancer treatment, the emergence of biosimilars as a lower-cost option has seen exponential growth.
Sameek Roychowdhury, MD, PhD, discusses the rationale for targeting FGFR mutations in cholangiocarcinoma and urothelial carcinoma, the potential efficacy of irreversible pan-FGFR inhibitors in these populations, and how continued research in this area may yield more personalized therapeutic approaches for patients with FGFR mutations.
Non-Hispanic Black patients with hormone receptor–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, according to an analysis of the phase 3 RxPONDER trial.
The addition of 1 year of everolimus to adjuvant endocrine therapy did not demonstrate a statistically significant improvement in invasive disease-free survival or overall survival in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer.
The combination of ribociclib plus endocrine therapy yielded a 46% reduction in the risk of disease progression or death compared with chemotherapy in pre/perimenopausal patients with aggressive hormone receptor–positive/HER2-negative advanced breast cancer.
Chemotherapy prior to treatment with endocrine therapy could increase the risk of cancer-related cognitive impairment compared with endocrine therapy alone in women with breast cancer, irrespective of menopausal status.
Tumor microenvironment of metastasis doorway density—a biomarker of distant metastatic recurrence—is higher in Black women vs White women with estrogen receptor–positive/HER2-negative breast cancer who have residual disease after neoadjuvant chemotherapy.
The development of zandelisib for the treatment of B-cell malignancies has been discontinued outside of Japan.
Press Release
More than 160 attendees took part in a day of learning and collaboration as Sylvester Comprehensive Cancer Center hosted the inaugural Cancer Survivorship Symposium.
Press Release
Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 44th annual San Antonio Breast Cancer Symposium on December 7-10th.
The FDA has granted a breakthrough therapy designation to revumenib for the treatment of adult and pediatric patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.
As new classes of agents deliver promising results for patients with HER2-mutant non–small cell lung cancer, new questions surrounding optimal identification tactics, sequencing, and treatment of patients arise.
The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.
Erika P. Hamilton, MD, discusses anticipated updates from DESTINY-Breast02 and DESTINY-Breast03 that will be presented at the 2022 San Antonio Breast Cancer Symposium, how trastuzumab emtansine will fit into the armamentarium in light of the efficacy of trastuzumab deruxtecan, and additional data to expect from SABCS regarding ADCs and beyond.
